Last checked at 29 Jan 2019 16:11
29 January 2019
Deltex Medical Group plc("Deltex Medical" or "the Company")
Exercise of Options
Deltex Medical Group plc (AIM DEMG) was notified on 29 January 2019 that certain employees have acquired 8,695,652 ordinary shares of 1p each ("Option Shares"), as the result of the exercise of options under the Company's 2003 Share Scheme. The options had an exercise price of 1 penny per share.
Accordingly, application has been made for the Option Shares to be admitted to trading on AIM. The Option Shares will rank pari passu with the existing issued shares of the Company and dealings are expected to commence on 4 February 2019.
The total number of ordinary shares in issue following Admission will be 501,359,019. The Company does not hold any shares in treasury. Accordingly, the figure of 501,359,019 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 |
Nigel Keen, Chairman | investorinfo@deltexmedical.com |
Andy Mears, Chief Executive | |
Jonathan Shaw, Group Finance Director | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Ciaran Walsh Dan Gee-Summons | |
Joint Broker | |
Turner Pope Investments (TPI) Ltd | 0203 621 4120 |
Andy Thacker | info@turnerpope.com |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal doppler monitoring ("ODM") (TrueVue Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in flow and measures such changes in 'real time'. Deltex Medical has been the only Group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue Doppler, which has been demonstrated to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for high risk surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.
The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA - and through distribution arrangements in approximately 40 other countries.